Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
批准号:
8149241
负责人:
Tomoshige Kino
金额:
$45.56万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
我们已经证明,几种人类状态的特征是中枢应激系统的活动过度或活动减退,这不仅解释了情绪变化,而且还解释了患有此类疾病的患者发展发育,代谢,心血管或自身免疫并发症的倾向。我们目前正在进行临床前研究与新发现的非肽类,口服,CRH 1型受体拮抗剂,antalarmin,这表明,这样的拮抗剂可能是有用的,在大量的状态,其特征在于过度活跃的压力系统,如抑郁症,神经性厌食症和特发性失眠。
在应激系统靶组织水平,我们通过定义糖皮质激素受体基因的新突变和/或缺失导致受体功能异常或减少,阐明了散发性和家族性糖皮质激素抵抗的分子病理生理学。我们发现一个女孩的情况下,杂合子取代精氨酸谷氨酰胺在氨基酸714(GR R714 Q)谁表现出加速骨龄和轻度阴蒂肥大,表明该患者有升高的雄激素作用引起的HPA和HPG轴的失调。在同一领域,我们描述了炎症诱导的糖皮质激素抵抗和糖皮质激素分泌不足的急性呼吸窘迫综合征。我们以前曾报道过,CLOCK/BMAL 1,自振荡转录因子,产生昼夜节律在中枢神经系统和外周,有节奏地抑制GR诱导的转录活性,表明CLOCK/BMAL 1的功能作为一个反相负调节糖皮质激素作用的靶组织,可能通过拮抗生物作用的昼夜波动循环糖皮质激素。我们进行了一项人体研究,发现CLOCK对GR转录活性的负调控在人体中也有功能。此外,非编码(nc)RNA生长停滞特异性5(Gas 5),其在生长停滞细胞中积累,但其生理作用尚不清楚,以及腺苷5'单磷酸活化蛋白激酶(AMPK),能量稳态的主要调节剂,感测体内的能量消耗并刺激增加燃料摄取和节省外周供应的途径,调节GR的转录活性。前者通过充当诱饵RNA GRE来实现这一点,后者通过磷酸化GR。这些结果表明,HPA轴的生物学作用在靶组织的水平上由营养状态和能量资源的可用性来调节。在由HPA和HPG轴的中枢成分组成的脑中,我们发现细胞周期蛋白依赖性激酶5(CDK 5)在CNS的形态发生和功能中起重要作用,并且其异常激活与神经退行性疾病的发展相关,与GR和盐皮质激素受体(MR)通过其激活剂p35/p25和差异调节这些类固醇受体的转录活性。内源性糖皮质激素皮质醇和皮质酮在中枢神经系统中与这些受体结合并引起受体特异性的生物学作用,而其靶分子之一的脑源性生长因子(brain-derived growth factor,BDNF)在神经生物学、突触可塑性、记忆巩固和情绪变化中起着关键作用。因此,CDK 5的异常激活可能通过皮质类固醇受体/BDNF部分调节神经元活性,进一步影响HPA的活性,并可能影响HPG轴。我们现在正在开发表达具有特定磷酸化位点或乙酰化位点的GR突变体的小鼠,以在动物水平上检查GR的这些表观遗传修饰的作用。
细胞外高渗透压或渗透压应激是陆地生物的主要威胁,因此通过下丘脑/垂体后叶分泌精氨酸加压素强烈刺激HPA轴。除了这种全身性反应外,它还激活了对细胞外高渗的适应性反应的细胞级联反应。细胞外高渗透压或渗透压应激诱导并激活含有Rel同源结构域的转录因子,即活化T细胞的核因子5(NFAT 5),其随后刺激渗透压应激应答基因的转录,并引起小的有机渗压物质的细胞内积累以维持细胞内外之间的等渗性。我们以前报道了一个细胞内信号级联反应的渗透压在淋巴细胞作为一个模型组织,并发现Rho型鸟嘌呤核苷酸交换因子(GEF)Brx或AKAP 13是必不可少的渗透压刺激的NFAT 5的表达,是细胞内信号级联传递细胞外高渗信号到细胞核的关键组成部分。渗透应激介导的NFAT 5诱导需要Brx GEF结构域和p38促分裂原活化激酶(MAPK),而响应于渗透应激的Brx通过其C-末端结构域吸引cJun激酶(JNK)-相互作用蛋白(JIP)4,其是对p38 MAPK级联和NFAT 5的活化具有特异性的支架,将活化的Rho型小G蛋白偶联至p38 MAPK信号传导途径的组分。重要的是,该信号系统在脾中的淋巴细胞分化中起关键作用,同时它是大多数器官和组织保护它们免受细胞外高渗并维持其功能的一般机制。为了进一步阐明Brx/NFAT 5介导的渗透应激对免疫功能调节的作用,我们现在正在使用Cre/LoxP系统开发在树突状细胞/单核细胞/巨噬细胞中携带特异性缺失brx基因的小鼠。
英文摘要
We have demonstrated that several human states are characterized by hyperactivity or hypoactivity of the central stress system, which explains not only mood changes but also the propensity of patients with such disorders to develop developmental, metabolic, cardiovascular or autoimmune complications. We are currently performing preclinical studies with the newly discovered nonpeptide, oral, CRH type 1 receptor antagonist, antalarmin, which show that such an antagonist may be useful in a large number of states characterized by hyperactivity of the stress system, such as depression, anorexia nervosa and idiopathic insomnia.
At the level of the stress system target tissues, we have elucidated the molecular pathophysiology of sporadic and familial glucocorticoid resistance by defining novel mutations and/or deletions of the glucocorticoid receptor gene leading to abnormally functioning or decreased receptors. We found a girl case with hetrozygotic replacement from arginine to glutamine at amino acid 714 (GR R714Q) who demonstrated accelerated bone age and mild clitolomegaly, indicating that this patient has elevated action of androgen caused by dysregulation of the HPA and HPG axes. In the same area, we have described inflammation-induced glucocorticoid resistance and glucocorticoid secretion insufficiency in the acute respiratory distress syndrome. We have previously reported that CLOCK/BMAL1, the self-oscillating transcription factors that generate circadian rhythms in both the central nervous system and periphery, rhythmically repressed GR-induced transcriptional activity, indicating that CLOCK/BMAL1 functions as a reverse phase negative regulator of glucocorticoid action in target tissues, possibly by antagonizing the biologic actions of diurnally fluctuating circulating glucocorticoids. We performed one human study and revealed that this negative regulation on GR transcriptional activity by CLOCK was also functional in humans. Furthermore, the noncoding (nc) RNA growth arrest-specific 5 (Gas5), which accumulates in growth-arrested cells, but whose physiologic roles are not known as yet, and the adenosine 5' monophosphate-activated protein kinase (AMPK), a master regulator of energy homeostasis, sensing energy depletion inside the body and stimulating pathways that increase fuel uptake and save on peripheral supplies, regulated transcriptional activity of the GR. The former accomplished this by acting as a decoy RNA GRE, the latter by phosphorylating the GR. These results indicate that the biologic actions of the HPA axis are regulated at the level of the target tissues by the nutritional state and availability of energy resources. In the brain, which consists of central component of the HPA and HPG axis, we found that the cyclin-dependent kinase 5 (CDK5), which plays important roles in the morphogenesis and functions of CNS, and whose aberrant activation is associated with development of neurodegenerative disorders, interacted with both GR and the mineralocorticoid receptor (MR) through its activators p35/p25 and differentially regulated the transcriptional activity of these steroid receptors. Endogenous glucocorticoids, cortisol and corticosterone, bind these receptors and cause receptor-specific biologic actions in CNS, while one of their target molecules, the brain-derived growth factor (BDNF) plays a critical roles in the neurobiability, synaptic plasticity, consolidation of memory and emotional changes. Therefore, aberrant activation of CDK5 may in part regulate neuronal activity through corticosteroid receptors/BDNF, further influencing the activity of the HPA, and possibly, the HPG axis. We are now developing mice expressing GR mutants with specific phosphorylation sites or acetylation sites in order to examine roles of these epigenetic modifications of GR at animal levels.
Extracellular hyperosmolarity or osmotic stress is a major threat for land organisms, and thus strongly stimulates the HPA axis through secretion of ariginine vasopression from the hypothalamus/posterior lobe of the pituitary gland. In addition to this systemic response, it also activates a cellular cascade of adaptive response to extracellular hyperosmolarity. Extracellular hyperosmolarity or osmotic stress induces and activates a Rel-homology domain-containing transcription factor, the nuclear factor of activated T-cells 5 (NFAT5), which subsequently stimulates transcription of osmotic stress-responsive genes and causes intracellular accumulation of small organic osmolytes to maintain isotonicity between the inside and outside of the cells. We previously reported an intracellular signaling cascade responsive to osmotic stress in lymphocytes as a model tissue, and found that a Rho-type guanine nucleotide exchange factor (GEF) Brx or AKAP13 is essential for the osmotic stress-stimulated expression of NFAT5, and is a key component of the intracellular signaling cascade transmitting the extracellular hyperosmolarity signal to the nucleus. Osmotic stress-mediated induction of NFAT5 requires the Brx GEF domain and p38 mitogen-activated kinase (MAPK), while Brx in response to osmotic stress attracts through its C-terminal domain the cJun kinase (JNK)-interacting protein (JIP) 4, a scaffold specific to activation of the p38 MAPK cascade and NFAT5, coupling activated Rho-type small G-proteins to components of the p38 MAPK signaling pathway. Importantly, this signaling system plays a critical role in the lymphocyte differentiation in the spleen, while it is a general mechanism for most of the organs and tissues to protect them from extracellular hyperosmolarity and to maintain their functions. To further elucidate roles of Brx/NFAT5-mediated osmotic stress on the regulation of immune function, we are now developing mice carrying specific deletion of the brx gene in dendritic cells/monocytes/macrophages using the Cre/LoxP system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mediators and Regulators of Glucocorticoid Actions
-
批准号:8351165
-
项目类别:
-
资助金额:$160.15万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators/Regulators of Glucocorticoid Actions
-
批准号:7209191
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Actions
-
批准号:7734762
-
项目类别:
-
资助金额:$28.88万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Act
-
批准号:7332773
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
-
批准号:8941436
-
项目类别:
-
资助金额:$16.1万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
-
批准号:7734695
-
项目类别:
-
资助金额:$28.87万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
-
批准号:8351107
-
项目类别:
-
资助金额:$53.38万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Endocrine-immune-reproductive System Interactions
-
批准号:7968513
-
项目类别:
-
资助金额:$46.5万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Actions
-
批准号:7968640
-
项目类别:
-
资助金额:$46.5万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Endocrine-immune-reproductive System Interactions
-
批准号:8736815
-
项目类别:
-
资助金额:$17.47万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Endocrine-immune-reproductive System Interactions
-
批准号:8941435
-
项目类别:
-
资助金额:$16.1万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Endocrine-immune-reproductive System Interactions
-
批准号:8553844
-
项目类别:
-
资助金额:$19.97万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
-
批准号:8553845
-
项目类别:
-
资助金额:$19.97万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Actions
-
批准号:8941482
-
项目类别:
-
资助金额:$48.31万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
-
批准号:8736816
-
项目类别:
-
资助金额:$17.47万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Act
-
批准号:6993547
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Actions
-
批准号:8553900
-
项目类别:
-
资助金额:$59.92万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Endocrine-immune-reproductive System Interactions
-
批准号:8351106
-
项目类别:
-
资助金额:$53.38万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Molecular Mediators and Regulators of Glucocorticoid Actions
-
批准号:7594207
-
项目类别:
-
资助金额:$22.23万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
Endocrine-immune-reproductive System Interactions
-
批准号:8149240
-
项目类别:
-
资助金额:$45.56万
-
财政年份:--
-
负责人:Tomoshige Kino
-
依托单位:
海外基金